GRANULES Stock Overview
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹417.95 |
| 52 Week High | ₹480.45 |
| 52 Week Low | ₹272.35 |
| Beta | 0.29 |
| 1 Month Change | -3.61% |
| 3 Month Change | 0.91% |
| 1 Year Change | 38.30% |
| 3 Year Change | 26.08% |
| 5 Year Change | 275.85% |
| Change since IPO | 3,912.96% |
Recent News & Updates
Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08
Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Recent updates
Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Many Still Looking Away From Granules India Limited (NSE:GRANULES)
Dec 28Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Nov 13A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)
Oct 24Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
May 19Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?
Mar 29Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Jan 19Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
Oct 01Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Aug 18Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75
Jul 14Is Granules India (NSE:GRANULES) A Risky Investment?
Jun 28Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75
Jun 09Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)
May 06Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25
Feb 10Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Feb 02Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Dec 21Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock
Aug 18Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25
Aug 03Is Granules India (NSE:GRANULES) Using Too Much Debt?
Jun 11Why Granules India Limited (NSE:GRANULES) Is A Dividend Rockstar
May 02Does This Valuation Of Granules India Limited (NSE:GRANULES) Imply Investors Are Overpaying?
Mar 26What Kind Of Investors Own Most Of Granules India Limited (NSE:GRANULES)?
Mar 14These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Mar 01Granules India Limited (NSE:GRANULES) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Feb 16Why You Might Be Interested In Granules India Limited (NSE:GRANULES) For Its Upcoming Dividend
Feb 03Analysts Have Made A Financial Statement On Granules India Limited's (NSE:GRANULES) Third-Quarter Report
Jan 30Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20
Have Insiders Sold Granules India Limited (NSE:GRANULES) Shares Recently?
Jan 07Announcing: Granules India (NSE:GRANULES) Stock Increased An Energizing 198% In The Last Year
Dec 28Granules India Limited's (NSE:GRANULES) Attractive Combination: Does It Earn A Place In Your Dividend Portfolio?
Dec 15Could The Granules India Limited (NSE:GRANULES) Ownership Structure Tell Us Something Useful?
Dec 02Shareholder Returns
| GRANULES | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.8% | 1.4% | 2.8% |
| 1Y | 38.3% | 57.2% | 46.6% |
Return vs Industry: GRANULES underperformed the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: GRANULES underperformed the Indian Market which returned 46.4% over the past year.
Price Volatility
| GRANULES volatility | |
|---|---|
| GRANULES Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: GRANULES has not had significant price volatility in the past 3 months.
Volatility Over Time: GRANULES's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 3,650 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other products for oncology.
Granules India Limited Fundamentals Summary
| GRANULES fundamental statistics | |
|---|---|
| Market cap | ₹101.21b |
| Earnings (TTM) | ₹3.95b |
| Revenue (TTM) | ₹45.26b |
25.6x
P/E Ratio2.2x
P/S RatioIs GRANULES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRANULES income statement (TTM) | |
|---|---|
| Revenue | ₹45.26b |
| Cost of Revenue | ₹22.60b |
| Gross Profit | ₹22.66b |
| Other Expenses | ₹18.71b |
| Earnings | ₹3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.31 |
| Gross Margin | 50.06% |
| Net Profit Margin | 8.73% |
| Debt/Equity Ratio | 46.5% |
How did GRANULES perform over the long term?
See historical performance and comparison